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AbstrACt
Objectives our aim was to use the opportunity 
provided by the European Scleroderma observational 
Study to (1) identify and describe those patients with 
early diffuse cutaneous systemic sclerosis (dcSSc) with 
progressive skin thickness, and (2) derive prediction 
models for progression over 12 months, to inform future 
randomised controlled trials (rCts).
Methods the modified rodnan skin score (mrSS) was 
recorded every 3 months in 326 patients. ’progressors’ 
were defined as those experiencing a 5-unit and 25% 
increase in mrSS score over 12 months (±3 months). 
Logistic models were fitted to predict progression and, 
using receiver operating characteristic (roC) curves, were 
compared on the basis of the area under curve (AUC), 
accuracy and positive predictive value (ppV).
results 66 patients (22.5%) progressed, 227 (77.5%) 
did not (33 could not have their status assessed due 
to insufficient data). progressors had shorter disease 
duration (median 8.1 vs 12.6 months, p=0.001) and 
lower mrSS (median 19 vs 21 units, p=0.030) than non-
progressors. Skin score was highest, and peaked earliest, 
in the anti-rnA polymerase III (pol3+) subgroup (n=50). 
A first predictive model (including mrSS, duration of 
skin thickening and their interaction) had an accuracy 
of 60.9%, AUC of 0.666 and ppV of 33.8%. By adding 
a variable for pol3 positivity, the model reached an 
accuracy of 71%, AUC of 0.711 and ppV of 41%.
Conclusions two prediction models for progressive 
skin thickening were derived, for use both in clinical 
practice and for cohort enrichment in rCts. these models 
will inform recruitment into the many clinical trials of 
dcSSc projected for the coming years.
trial registration number nCt02339441.
IntrOduCtIOn
Patients with the diffuse cutaneous subtype of 
systemic sclerosis (dcSSc) have high morbidity and 
mortality, associated with the degree of severity of 
skin fibrosis/thickening as assessed by the modi-
fied Rodnan skin score (mRSS).1 2 The mRSS, as 
well as being a key clinical tool that clinicians use 
to monitor patients in everyday clinical practice, 
is usually the primary end point in randomised 
controlled trials (RCTs) of dcSSc. These trials 
pose particular challenges first because dcSSc is a 
rare disease, and second because mRSS tends to 
rapidly progress over time (usually within the first 
3–5 years), but then to ‘plateau’ and often subse-
quently fall,3 probably contributing to why several 
treatments associated with benefit in open-label or 
observational studies have not conferred benefit 
in RCTs.4–7 Ideally, we need to be able to predict 
which patients are likely to progress in terms of 
mRSS and recruit from this subset into RCTs. Most 
RCTs have restricted inclusion to patients with 
early disease (some within 18 months of onset of 
skin thickening,5 8 others within 3–5 years9–12). 
More recently, it has been suggested that an upper 
mRSS cut-off could further enrich the cohort for 
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worsening skin,13 14 with 22 as a proposed level.13 However, the 
stricter the inclusion criteria, inevitably the more difficult it will 
be to recruit. This is a key issue: recent advances are driving 
new approaches to therapy, and recruitment is now increasingly 
difficult with competing studies.
The European Scleroderma Observational Study (ESOS)15 
was a prospective observational study of treatment outcome 
in 326 patients with early dcSSc. Patients were assessed every 
3 months for 12–24 months (most for 24 months), with mRSS 
documented at each visit. Thus, ESOS provided a unique oppor-
tunity to perform a detailed study of mRSS trajectory over time 
in a large multinational cohort with very early disease (median 
disease duration from onset of skin thickening: 11.9 months). 
Our aim was twofold: (1) for the practising clinician, to iden-
tify and describe (in the ESOS cohort) patients with progressive 
skin thickness; and (2) for the clinical trialist, to derive predic-
tion models for progression over 12 months, in order to inform/
maximise recruitment into future RCTs.
MetHOds
esOs study design and patients
This is described fully elsewhere15: patients with early dcSSc 
were recruited into a prospective, observational cohort 
study comparing the effectiveness of four different treat-
ment protocols. The main inclusion criteria were early dcSSc 
(skin involvement extending proximal to elbow or knee and/
or involving trunk,16 and within 3 years of the onset of skin 
thickening as judged by physician at screening visit) and 
age >18 years. Patients attended every 3 months for 12–24 
months. The primary outcome measure was the mRSS. Demo-
graphic and clinical characteristics including age, gender, 
smoking habit, ethnicity, antibody status (antitopoisomerase-1 
(anti-Scl-70, ‘TOPO’), anti-RNA polymerase III (‘Pol3’), anti-
centromere (‘ACA’)) and presence of visceral organ involvement 
were recorded for all patients.15 There were 326 patients from 
50 centres (19 countries) who were recruited: 65 started on 
methotrexate, 118 on mycophenolate mofetil, 87 on cyclophos-
phamide and 56 no immunosuppressant. Four patients who 
were found postrecruitment to have a baseline duration of skin 
thickening >36 months (up to 44.6) were retained (a subsid-
iary analysis verified the robustness of our predictive models to 
their inclusion). Because progression status did not significantly 
differ between treatment groups, mRSS trajectories were anal-
ysed irrespective of treatment protocol (online supplementary 
table S1). Each patient gave written informed consent.
definition of progressive patients
Disease progression was defined in terms of mRSS worsening, 
in line with most recent RCTs. For the univariate analysis and 
predictive models, patients with progressive disease (‘progres-
sors’) are defined as those with a 5-unit and 25% increase in 
their mRSS between baseline and their highest subsequent score. 
This threshold is generally considered to reflect meaningful 
change in mRSS progression,17 thus enabling model compari-
sons.13 14 18 We considered only peaks occurring during the 
first 12±3 months after baseline, using all 3-monthly obser-
vations. The time window was chosen because it is considered 
an appropriate period to detect clinically meaningful changes 
in the skin score.19 Most cases of progression occurred early: 
extending the time period to 24 months would have added only 
four additional ‘progressors’ and would have lost comparability 
with other published models of progression which examined a 
12-month window.13 14 18
To distinguish between non-progressors and patients with 
insufficient data to describe their status, data requirements were 
set up as detailed in table 1 footnote (*).
univariate analysis
The univariate analysis compared progressors and non-progres-
sors according to patient characteristics using the Kruskal-Wallis 
(for continuous variables) or Fisher’s test (for categorical 
variables). To characterise the progression of skin thickening 
according to autoantibody status, those same tests assessed 
differences in distribution for certain features (such as disease 
duration and mRSS peak) between autoantibody groups.
table 1 Characteristics of progressors and non-progressors according to clinical features and autoantibody status (at baseline) 
Characteristics Progressor, n=66 (22.5%) non-progressor, n=227 (77.5%) P total, n=293 (100%)
Missing at 
baseline, n (%)
mRSS (0–51) 19 (16–23) 21 (16–27) 0.030 21 (16–26) 0 (0)
Months since onset of skin thickening 8.1 (4.7–16.0) 12.6 (8.1–22.0) 0.001 12.0 (7.0–21.0) 14 (4.8)
Pulmonary fibrosis, n (%) 9 (13.6) 31 (13.7) 1 40 (13.7) 0 (0)
FVC (% predicted) 87.5 (72.0–101.0) 91.0 (75.0–102.0) 0.129 90.0 (75.0–102.0) 16(5.5)
DLCO (% predicted) 62.8 (49.0–76.5) 66.0 (52.0–79.0) 0.455 65.0 (50.0–79.0) 31 (10.6)
Pulmonary hypertension, n (%) 1 (1.5) 19 (8.4) 0.054† 20 (6.8) 1 (0.3)
Antitopoisomerase (anti-Scl70) (TOPO), n (%) 30 (46.2) 84 (38) 0.252 114 (39.9) 7 (2.4)
Anti-RNA polymerase III (Pol3), n (%) 14 (25.9) 34 (18.5) 0.249 48 (20.2) 55 (18.8)
Anticentromere (ACA), n (%) 5 (7.7) 14 (6.4) 0.777 19 (6.7) 8 (2.7)
No autoantibodies (TOPO, Pol3 or ACA), n (%) 7 (12.7) 52 (28.4) 0.020 59 (24.8) 55 (18.8)
Median (IQR) unless otherwise indicated.
P values refer to the Kruskal-Wallis (for continuous variables) or Fisher’s test (for categorical variables).
This table compares the distribution of patient characteristics at baseline between progressors and non-progressors, using the subset of 293 for whom the progression status is 
known. To distinguish between non-progressors and patients with insufficient data to describe their status, data requirements were set up. If progression was not detected using 
all data from the first >12±3 months, patients needed at least two data points to be considered non-progressors: one at baseline and another at least 5 months after baseline. 
Otherwise, we considered there were not enough data to ascertain their status. The 5-month limit was chosen so that all visits in the vicinity of the 6-month study mark could be 
counted.
†The presence of pulmonary hypertension was not included as a variable in prediction models for progression. Only one patient had pulmonary hypertension and progressed. 
Thus, a prediction model using mRSS, duration of skin thickening, an mRSS/duration interaction and the presence of pulmonary hypertension was too restrictive: no combinations 
of mRSS and duration of skin thickening enabled patients with pulmonary hypertension to progress.
DLCO, diffusing capacity for carbon monoxide; FVC, forced vital capacity; mRSS, modified Rodnan skin score.
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If a patient tested positive for an autoantibody, we assumed 
they did not have the other two if those data were missing. 
Patients with more than one autoantibody were excluded from 
our models.
Predictive models of mrss progression
Logistic regressions were fitted to predict progression using 
baseline characteristics. Associations with progression (including 
those in table 1) and the predictive performance of single predic-
tors were assessed to select potential covariates, resulting in 
different models.
Those models were then compared on the basis of the area 
under curve (AUC), sensitivity, specificity, positive predictive 
value (PPV) and accuracy at each curve’s optimal point—but 
also according to their simplicity and interpretability. Predictive 
ability can be optimistic when assessed using its own model-gen-
erating data. An additional optimism-adjusted bootstrapped AUC 
was therefore also computed and reported in online supplemen-
tary table S2, suggesting modest corrections.20 Calibration plots 
for the retained models were also assessed.21
When including autoantibodies in predictive models, certain 
specifications produced predicted progression probabilities 
that were too low for certain subgroups and were thus avoided 
because they were considered too restrictive to apply in practice. 
Consequently, patients were only classed according to their 
Pol3 positivity rather than having indicator variables for each 
autoantibody (see note (1) in figure 3 and online supplementary 
table S2).
results
univariate analysis: associates of mrss progression and 
autoantibody status
The characteristics of mRSS progression are summarised in 
figure 1, including the increase in mRSS and the peak reached. 
During the study, the median number of skin scores recorded 
for each patient was 7 over a median follow-up of 23.4 months. 
There were 160 patients who had an increase in mRSS (of any 
magnitude) during the study (149 during the first 12 (±3) 
months).
Characteristics of progressors versus non-progressors
Out of 326 patients recruited at baseline, based on the retained 
progression criterion, 66 (22.5%) progressed and 227 (77.5%) 
did not (table 1). Progression status could not be assessed in 33 
patients: 16 had no postbaseline skin scores and 17 did not fulfil 
the data requirements to ascertain progression status (see foot-
note (*) of table 1). Among those 33 patients with unknown 
status, 12 (36.4%) died during the analysis period.
At the time of recruitment, progressors had shorter disease 
duration than those who did not progress (median 8.1 vs 12.6 
months (P=0.001)).
In addition, progressors tended to start with lower skin scores, 
median mRSS of 19 units, compared with 21 for non-progres-
sors (P=0.030). Nevertheless, 30.3% of progressors started 
with mRSS >22 units and 15.2% with mRSS >25 units (online 
supplementary figure S1).
Characteristics of mRSS progression according to autoantibody 
status
Out of the 326 patients, 124 were TOPO+, 50 were Pol3+, 
20 were ACA+, 2 were TOPO+/ACA+, 68 were autoanti-
body-negative and 62 could not have their status determined: in 
51 cases, this was because the Pol3 test was not done (unavail-
able in some centres) and the patient had neither TOPO nor 
ACA antibodies (table 2).
At baseline, Pol3+ patients had higher mRSS than patients in 
the other autoantibody groups (P=0.003) despite similar disease 
durations (P=0.593) (table 2).
There was a trend for Pol3+ patients to be more likely 
to progress than the other subgroups: 29.2% were progres-
sors compared with 11.9% for the ‘no autoantibody’ group 
(P=0.105) (table 2). Pol3+ patients experienced higher increases 
in mRSS between baseline and peak: median increase of 7 units, 
compared with 3 for the ‘no autoantibody’ group (P=0.059) 
(table 2). Combined with their higher mRSS starting point, this 
results in Pol3+ patients having the highest peaks of all autoanti-
body groups with a median peak of 35 units (P=0.001) (table 2).
In terms of the speed of progression following onset, 
Pol3+ patients had the lowest observed median time to peak at 
16.3 months (P=0.199) (table 2).
Predictive models of mrss progression in first year of follow-
up
Univariate and multivariate predictive models
Online supplementary table S2 and figure 2 show the values asso-
ciated with the ROC curves for the multiple models tested, and 
online supplementary table S3 displays the details of different 
Figure 1 Characteristics of mRSS progression. The five histograms 
describe modified Rodnan skin score (mRSS) progression for all patients 
whose skin score during the study ever increases beyond their baseline 
level (n=160) and for those whose progression satisfies the 5-unit and 
25% increase rule during the first 12 months (±3 months) (n=66). Here, 
histograms summarise the distribution of changes between baseline 
and peak mRSS, the mRSS value at its peak, the time elapsed between 
the onset of skin thickening and the recorded peak, the rate of mRSS 
increase per month between baseline and peak, and the time elapsed 
between baseline and the recorded peak. The rate of mRSS progression 
(in units/month) was computed by specifying individual simple linear 
regressions of mRSS according to time, between baseline and peak.
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selected logistic models to predict progression and the regression 
outputs. As a single predictor for progression, mRSS performed 
poorly with an AUC of 0.588 (95% CI 0.515 to 0.661). Duration 
of skin thickening performed better on its own, with an AUC 
of 0.634 (95% CI 0.553 to 0.715). A model combining mRSS, 
disease duration and an interaction between the two improved 
those univariate performances, with an AUC of 0.666 (95% CI 
0.597 to 0.736). In addition, that model had a high 73.4% sensi-
tivity, alongside its 57.2% specificity, and accurately predicted 
60.9% of cases.
The interaction between mRSS and disease duration indicated 
that future progressors presented at their first visit with earlier 
disease and lower skin scores, and that higher skin score usually 
had to be compensated by lower disease duration for progres-
sion to occur (figure 3). Graphically, this could be identified by 
noting that, in figure 3 (model A), the points indicating progres-
sors were mostly contained within the triangular lower half of 
a rectangle.
Adding an indicator variable for Pol3 positivity induced 
further gains in the model (already including mRSS, duration 
and their interaction), yielding an AUC of 0.711 (95% CI 0.633 
to 0.790), 60.4% sensitivity, 74.2% specificity and accurately 
predicting 71% of cases (online supplementary table S2).
By graphical assessment, model A appeared to be better cali-
brated than the one including only mRSS, and model B appeared 
to improve on model A (online supplementary figure S2). The 
predicted probabilities for models A and B are summarised in 
online supplementary figures S3 and S4.
Properties of predictive models and application in practice
Two models described above were retained: model A and model 
B, which also includes Pol3+ status (figure 3, online supplemen-
tary table S2). Their ROC curves are shown in figure 2, and each 
curve yielded an optimal point nearest to the top-left corner, 
representing a threshold probability of progression. If a patient’s 
predicted probability was above this threshold, it was predicted 
that she/he would progress. Thus, for each level of disease dura-
tion at baseline, there corresponded an entry mRSS under which 
a patient met that threshold (summarised and plotted in table 3 
table 2 Characteristics of mRSS progression according to autoantibody status
Autoantibody make-up
Anti-tOPO-isomerase 
(anti-scl70) (tOPO)
Anti-rnA polymerase 
III (Pol3) Anticentromere (ACA) none
total
P
Missing at 
baseline, n (%)
(tOPO+)
(Pol3– or n/A)
(ACA– or n/A)
(tOPO– or n/A)
(Pol3+)
(ACA– or n/A)
(tOPO– or n/A)
(Pol3– or n/A)
(ACA+)
(tOPO−)
(Pol3−)
(ACA−)
n=124 (47.3%) n=50 (19.1%) n=20 (7.6%) n=68 (26.0%) n=262 (100%)
mRSS at baseline (0–51) 19 (15–25.5) 24 (19-31) 20 (17–24.5) 20 (16–24) 20 (16–26) 0.003 0 (0)
mRSS peak* 26 (19.5–33.5) 35 (26–40) 29 (26–35) 24.5 (17.5–29) 27 (21–34.5) 0.001 0 (0)
Difference in mRSS between 
baseline and peak*
5 (3–10.5) 7 (3–10) 4 (4–11) 3 (1.5–7) 5 (3–10) 0.059 0 (0)
Months since onset of skin 
thickening (at baseline)
12.6 (6.2–21.6) 11.2 (7.8–17.9) 14.9 (5.4–24.0) 12.6 (9.2–21.9) 12.6 (7.3–21.5) 0.593 10 (3.8)
Months until peak since onset 
of skin thickening*
21.0 (12.9–31.6) 16.3 (12.9–21.4) 29.3 (15.5–35.7) 20.1 (13.2–32) 19.0 (12.9–30.0) 0.199 5 (3.9)
Months until peak since 
baseline* 6.4 (4.0–14.4) 5.8 (2.9–12.0) 6.5 (2.9–9.2) 6.0 (3.1–11.6) 6.2 (3.2–12.1) 0.329 0 (0)
Progressor (5 points and 25% 
according to baseline)
29 (25.9) 14 (29.2) 4 (23.5) 7 (11.9) 54 (22.9) 0.105 26 (9.9)
Median (IQR) unless otherwise indicated.
P values refer to the Kruskal-Wallis (for continuous variables) or Fisher’s test (for categorical variables).
*For these comparisons, an unrestricted definition of progression was used, meaning that all 160 patients in the cohort with mRSS progression of any magnitude were initially 
considered but only 128 of those could be included because of patients with missing autoantibody data.
This table includes comparisons of patient characteristics at baseline between different autoantibody groups, using the subset of 262 patients for whom the autoantibody status 
could be assessed.
mRSS, modified Rodnan skin score; N/A, not available.
Figure 2 ROC of three selected models. Three ROC curves summarise 
the predictive power of three different models by plotting sensitivity 
with respect to 100-specificity. For each model/ROC curve, there is an 
optimal point (the one closest to the top-left corner) that corresponds 
to a threshold of predicted probability of progression. For each model, 
patients with a predicted probability above that threshold are predicted 
to progress. AUC, area under curve; mRSS, modified Rodnan skin score; 
Pol3, anti-RNA polymerase III; PPV, positive predictive value; ROC, 
receiver operating characteristic. 
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and figure 3 for the two models). For instance, using the selec-
tion rule produced by model A, a patient recruited at 9 months 
of skin thickening would be predicted to progress if mRSS was 
between 0 and 23 units. However, if a patient presented at 6 
months, the mRSS would be allowed to go as high as 29.
If applying this selection rule (model A) to the ESOS cohort, 
139 patients (49.8% of the 279 patients included in the model) 
would be predicted to progress, of whom 47 actually did in 
the year following baseline (PPV: 33.8%). Conversely, 140 
were predicted not to progress, of whom 123 did not (negative 
predictive value (NPV): 87.9%), whereas 17 (12.1%) did. Model 
B is used in the same way as model A, but accounting for Pol3 
status. The curves in figure 3 (summarising selection criteria) 
Figure 3 Rules for selecting progressive patients according to two 
selected models. According to each model, in order to select progressive 
patients, they should be selected from the area under each relevant 
curve. These curves are superposed over a plot of the baseline mRSS 
of patients with respect to their duration of skin thickening, with 
progressors (of at least 5 units and 25%) being highlighted. Notes to the 
figure: (1) Analysing patients separately according to all autoantibody 
groups (TOPO, Pol3, ACA, ‘no autoantibodies’) was avoided because 
of the small number of ACA+ patients who could be included (n=16). 
Another possible approach was the inclusion of two indicator variables: 
one for Pol3+ and another for TOPO+, meaning that ACA+ and ‘no 
autoantibody’ patients formed the reference group, for which the 
resulting model proved too restrictive: only 2 out of 75 patients in 
the reference group were predicted to progress. Another reason for 
considering Pol3 patients separately was that they were suspected 
from preliminary analysis to be the most clinically different group, and 
stratifying by Pol3 status produced a higher AUC than doing so by TOPO 
status. (2) Each prediction model is based on a logistic regression model, 
where the outcome for patient i is Yi = progression and X are 
a selection of covariates. Using ROC curve analysis, each model has 
an optimal p∗ for which, if �Pr (Yi = 1|X) > p∗, the patient is 
predicted to progress. Each frontier in the graphs above corresponds 
to the combination of mRSS and disease duration points, for which �Pr (Yi = 1|X) = p∗ in the domains where both predictors are defined. 
Therefore, if a patient is in the area under the relevant curve, she/he 
is predicted to progress according to the model. ACA, anticentromere; 
AUC, area under curve; mRSS, modified Rodnan skin score; Pol3, anti-
RNA polymerase III; ROC, receiver operating characteristic; TOPO, 
topoisomerase.
table 3 Rules for selecting progressive patients according to two 
selected models
If duration of 
skin thickening 
is (months)
Model A Model b
AuC: 0.666
sensitivity: 73.4%
specificity: 57.2%
PPV: 33.8%
nPV: 87.9%
Accuracy: 60.9%
AuC: 0.711
sensitivity: 60.4%
specificity: 74.2%
PPV: 41.0%
nPV: 86.3%
Accuracy: 71.0%
All patients Pol3+ patients All others
mrss should be 
(units) or less
mrss should be 
(units) or less
mrss should be 
(units) or less
1 51 51 51
2 51 51 51
3 43 51 51
4 37 51 37
5 33 51 28
6 29 48 23
7 27 40 20
8 25 35 18
9 23 31 16
10 22 28 15
11 21 26 14
12 20 24 13
13 19 22 13
14 18 21 12
15 18 20 12
16 17 19 11
17 17 18 11
18 16 17 11
19 16 17 10
20 15 16 10
21 15 16 10
22 15 15 10
23 15 15 10
24 14 14 9
25 14 14 9
26 14 14 9
27 14 13 9
28 13 13 9
29 13 13 9
30 13 13 9
31 13 12 9
32 13 12 9
33 13 12 8
34 12 12 8
35 12 12 8
36 12 11 8
For each duration, the required mRSS level is rounded above to the nearest integer 
to reflect real mRSS values.
AUC, area under curve; mRSS, modified Rodnan skin score; PPV, positive predictive 
value.
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shift across the diagonal axis to reflect that Pol3+ patients have 
a higher propensity to progress during the first year compared 
with Pol3− patients.
Model B had a higher accuracy than model A (71.0%–
60.9%)%). Model B, which was more specific, was also more 
restrictive: only 78 patients were predicted to progress, of whom 
32 actually did (PPV: 41.0%). Therefore this model identified a 
‘high risk’ subset of patients with a proportion of progressors 1.8 
times higher than the overall cohort. In model B, 153 patients 
were predicted not to progress, of whom 132 did not (NPV: 
86.3%), whereas 21 did (13.7%).
The predictive power of model B was particularly strong for 
Pol3+ patients, for whom the sensitivity was 100% and the spec-
ificity was 70.6%.
dIsCussIOn
The major strength of this study compared with previous 
recent analyses of mRSS is that this was a well-defined cohort 
with prospective assessment of mRSS by experienced asses-
sors. Assessments every 3 months provide detailed insight 
into disease trajectory (and burden) for the practising clini-
cian. For the clinical trialist, the time frames examined were 
comparable to those of recent and current RCTs, which 
include assessments at 24 weeks (and less) as well as at 12 
months.12 22 In addition, as the data set was derived from an 
observational study of standard current treatments for skin, 
we expect that our findings are generalisable to current or 
future clinical trials of skin therapy in dcSSc. This is espe-
cially relevant since current trials often permit standard back-
ground therapy, as used in ESOS, to which a novel agent may 
be added. The key finding here was the development of a 
predictive model for mRSS (disease) progression which had 
an accuracy of 60.9% (model A), achieved by recognising that 
the initial skin score is a poor predictor of progression on 
its own and that prediction is improved by simultaneously 
accounting for disease duration. By including autoantibodies 
in this analysis, the model improved and reached an accuracy 
of 71.0% (model B).
When recruiting patients into clinical trials of rare diseases, 
any algorithm should not be too restrictive. Higher sensitivity 
was favoured because it was considered more appropriate to 
have more inclusive models at the risk of mischaracterising 
non-progressors as progressors. We believe that model A 
will be the more useful for studies aiming for cohort enrich-
ment, while model B will help to identify patients at higher 
risk for mRSS progression in a clinical setting. The use of the 
second model to inform patient selection into RCTs could risk 
over-representing Pol3+ patients, for whom the criteria to 
predict progression are less strict, thus yielding a sample not 
reflecting the overall dcSSc population.
Other ‘take home messages’ were that skin score progression 
did occur in some patients who presented with high baseline 
mRSS (25 or higher), although this tended to be compensated 
by shorter disease durations, that Pol3+ patients tended to 
reach their peak mRSS earlier than other patients, and that 
this peak was much higher than for patients with other (or 
no) autoantibodies. Patients without TOPO, Pol3 or ACA 
autoantibodies had smaller increases in mRSS and lower peak 
skin scores. Our 3-monthly data allowed us to capture peaks 
in mRSS, which would have been ‘smoothed over’ in other 
studies because of less frequent data. Had we only recorded 
baseline and 12-month data (two observations), 53% of our 
cases of progression would have been missed.
Taking into account peak mRSS in defining progression 
(as opposed to considering only baseline and 12 month data) 
was therefore a major difference between ESOS and the study 
by Maurer et al13 who also looked at prediction of extent of 
skin thickening in patients with systemic sclerosis in a study 
of 637 patients from the EULAR Scleroderma Trials and 
Research group  (EUSTAR) cohort and an average follow-up 
time between visits of 12 months (compared with 3-monthly 
in ESOS). Disease duration was 42 months (therefore substan-
tially longer than in the ESOS cohort) and baseline mRSS 
was 17 units (compared with a mean of 22.1 units for ESOS). 
ESOS had 22.5% of progressors compared with EUSTAR’s 
9.7%, possibly because ESOS was an earlier cohort and the 
3-monthly follow-ups made any disease progression more 
likely to be detected. Maurer et al13 established that lower 
mRSS and shorter disease duration were associated with more 
progressive cases, as confirmed here, although we accept that 
the two studies are not strictly comparable given the differing 
time frames of defining ‘progressors’.13
However, if we do apply a 22-unit mRSS cut-off point to the 
ESOS cohort, its size would decrease from 326 to 189, and the 
share of progressors (among those with known status) would 
only increase from 22.5% to 26.4%. In contrast, that share 
(PPV) rises to 33.8% with model A and 41.0% with model 
B. Like Maurer et al13 we found that skin score alone was a 
poor predictor for progression and that other factors including 
disease duration should also be considered.
Dobrota et al14 also looked at patterns of mRSS changes but 
focused on regression rather than progression, validating that 
a low baseline mRSS predicts progression.
Our study has certain limitations. It can be very difficult 
to gauge onset of skin thickening (in 18 (5.5%) patients we 
had no data on duration of skin thickening at baseline, other 
than that this was under 3 years). It is likely that in some 
patients (especially those who steadily improve after baseline), 
peak mRSS occurred prior to study entry. Also, unlike the 
EUSTAR study,13 we have not externally validated the model, 
and this will be an important step before using the models 
widely. Among the patients with unknown progression status, 
36.4% died, thus potentially inducing bias (it is likely they had 
progressive disease) but also mirroring the attrition occurring 
in clinical trials. In model B, missing data in autoantibodies 
(19.6%) reduce the predictive power.
In conclusion, among patients with early dcSSc, those with 
shorter disease duration and lower mRSS are most likely to 
be ‘progressors’ with a trade-off between the two factors, and 
patients who are Pol3+ have the highest mRSS peaks and tend 
to reach peak mRSS earliest, providing a valuable message 
for clinicians that patients with short disease duration and 
Pol3+ must be especially closely monitored. Two prediction 
models for progressive skin thickening were derived. The 
model incorporating Pol3 (model B) more accurately identifies 
high-risk patients, but risks being too restrictive for patient 
selection into trials and over-representing Pol3+ patients. 
Both models were more flexible (for a given skin score) and 
more accurate than a ‘22 mRSS’ cut-off model and may offer 
advantages for cohort enrichment in clinical trials to ensure 
that the most informative patients are included.
Author affiliations
1Centre for Musculoskeletal research, Salford royal nHS Foundation trust, 
Manchester Academic Health Science Centre, University of Manchester, Manchester, 
UK
2nIHr Manchester Musculoskeletal Biomedical research Centre, Central Manchester 
nHS Foundation trust, Manchester Academic Health Science Centre, Manchester, UK
569Herrick AL, et al. Ann Rheum Dis 2018;77:563–570. doi:10.1136/annrheumdis-2017-211912
Clinical and epidemiological research
3Centre for Musculoskeletal research, the University of Manchester, Manchester 
Academic Health Science Centre, Manchester, UK
4department of rheumatology, Lund University, Lund, Sweden
5Service de Medicine Interne, Hôpital Cochin, Centre de référence pour les 
Vascularites nécrosantes et la Sclérodermie Systémique, Université paris descartes, 
paris, France
6nuffield department of orthopaedics, rheumatology and Musculoskeletal Sciences, 
University of oxford, oxford, UK
7University of Manchester, Manchester, Greater Manchester, UK
8department of rheumatology and Immunology, Medical Center, University of pecs, 
pecs, Hungary
9department of Internal Medicine III, University of Erlangen-nuremberg, Erlangen, 
Germany
10department of rheumatology, University of Zurich, Zurich, Switzerland
11royal Free London nHS Foundation trust, London, UK
12rehabilitation Services, Salford royal nHS Foundation trust, Salford, UK
13department of the rheumatic diseases, radboud University nijmegen Medical 
Centre, nijmegen, the netherlands
14rheumatology 2 department, ’Grigore t. popa’ University of Medicine and 
pharmacy, Clinical rehabilitation Hospital, Iasi, romania
15UCL division of Medicine, Centre for rheumatology and Connective tissue 
diseases, London, UK
16Unite Clinique de Medicine Interne, Maladies Auto-immunes et pathologie 
Vasculaire, UF 04, Hôpital Saint-Louis, Ap-Hp Assistance publique des Hôpitaux de 
paris, InSErM UMrS 1160, paris denis diderot University, paris, France
17Jewish General Hospital, Lady davis Institute and McGill University, Montreal, 
Canada
18department of Experimental and Clinical Medicine, division of rheumatology 
AoUC, University of Florence, Florence, Italy
19Shine rheumatology Unit, rambam Health Care Campus, rappaport Faculty of 
Medicine, Haifa, Israel
20rheumatology Unit, oslo University Hospital rikshospitalet, oslo, norway
21Queen Elizabeth Hospital Birmingham, UHB Foundation trust, Birmingham, UK
22St Vincent’s Hospital, Melbourne, Victoria, Australia
23department for dermatology, University of Cologne Kerpener Str, Cologne, 
Germany
24Cambridge University nHS Hospital Foundation trust, Cambridge, UK
25department of Internal Medicine, Hôtel-dieu Hospital, University of nantes, nantes, 
France
26University of Liverpool, Aintree University Hospital, Liverpool, UK
27Service de Médecine Interne, Hôpital Bretonneau tours, tours, France
28Centre for rheumatic diseases, royal Infirmary, Glasgow, UK
29Sheffield teaching Hospitals, Sheffield, UK
30Leeds Institute of rheumatic and Musculoskeletal Medicine, University of Leeds 
and nIHr Leeds Musculoskeletal Biomedical research Centre, Leeds teaching 
Hospitals nHS trust, Leeds, UK
31Stanford University, Stanford, California, USA
32University of Belgrade School of Medicine, Institute of rheumatology, Belgrade, 
Serbia
33Clinical and Academic rheumatology, north Bristol nHS trust, Bristol, UK
34nottingham University Hospitals nHS trust and nottingham nHS treatment Centre, 
nottingham, UK
35peter Maddison rheumatology Centre, Llandudno, UK
36Queens Hospital, romford, UK
37University of Copenhagen, Copenhagen Lupus and Vasculitis Clinic, Center for 
rheumatology and Spine diseases, rigshospitalet, Copenhagen, denmark
38norwich Medical School, University of East Anglia, norwich, UK
39royal national Hospital for rheumatic diseases, Bath, UK
40department of rheumatology and Clinical Immunology, Justus-Liebig University 
Giessen, Bad nauheim, Germany
41department of rheumatology, University of Lübeck, Lübeck, Germany
42department of rheumatology and Clinical Immunology, University Hospital Charité 
Berlin, Berlin, Germany
43department of rheumatology, royal perth Hospital, perth, Australia
44Servicio de reumatologia, Hospital Universitario 12 de octubre, Madrid, Spain
45Internal Medicine Unit, Limoges University Hospital, Limoges, France
46Centre national de référence Maladies Systémiques et Auto-immunes rares, 
département de Médecine Interne et Immunologie Clinique, Université de Lille, Lille, 
France
47Gateshead Hospitals Foundation trust, Gateshead, UK
48department of Internal Medicine, division of rheumatology, Istanbul University, 
Istanbul Medical Faculty, Istanbul, turkey
49Fife rheumatic diseases Unit, Whyteman’s Brae Hospital, Kirkcaldy, UK
50department of rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, the 
netherlands
51James Cook University Hospital, Middlesbrough, UK
52rheumatology Unit, royal Adelaide Hospital, and discipline of Medicine, University 
of Adelaide, Adelaide, Victoria, Australia
53department of rheumatology and Inflammation research, the Sahlgrenska 
Academy at Gothenburg University, Gothenburg, Sweden
54Monash Health and department Medicine, Monash Centre for Inflammatory 
diseases, Monash University, Melbourne, Victoria, Australia
55department of Internal Medicine, Hôpital Edouard Herriot, Lyon, France
56department of Internal Medicine, Foundation Hospital Saint Joseph, Marseille, 
France
57Cannock Chase Hospital, Cannock, UK
58St Vincent’s University Hospital, dublin, Ireland
59department of Internal Medicine, Centre Hospitalier Lyon Sud, Lyon, France
60Internal Medicine, Ambroise paré Hospital, Boulogne-Billancourt, France
Acknowledgements We are grateful to dr Holly Ennis for study set-up and for 
project coordination during the earlier phases of the study, and also to the members 
of the independent oversight board: Stephen Cole, dinesh Khanna and Frank 
Wollheim.
Contributors ALH, ML, rH, LM, AJS, EB, LaC, JHWd, od, KF, WJG, ro, MCV and 
Cpd were members of the European Scleroderma observational Study (ESoS) 
Steering Committee and designed the ESoS study. Sep and ML were responsible 
for the statistical analysis. ALH, rH, LaC, JHWd, od, MV, CoA, VHo, dF, MH, MM-C, 
AB-G, oM, pJ, ACJ, WS, pM, FCH, ChA, MEA, Ed, rM, MA, MHB, LoC, nSd, HG, 
pL, YA, KC, SJ, AJM, nM, UM-L, Gr, MB, Jr, pEC, A-LF, EH, JH, MI, JSM, JMvL, Sap, 
Sup, Ar, JS, BC, CS, tS, dJV, CG, G-St and Cpd were principal investigators at the 
different sites and recruited patients. xp and Gd were study coordinators. ALH, Sep, 
ML, rH, LM, AJS and Cpd wrote the draft report, and all authors reviewed the report 
and provided comments.
Funding ESoS was funded by a grant from the EULAr (European League Against 
rheumatism) orphan disease programme. Additional funding from Scleroderma and 
raynaud’s UK allowed a 1-year extension of the study.
Competing interests ALH has done consultancy work for Actelion, served on a 
data Safety Monitoring Board for Apricus, received research funding and speaker’s 
fees from Actelion, and speaker’s fees from GSK. JHWd has consultancy relationships 
and/or has received research funding from Actelion, BMS, Celgene, Bayer pharma, 
Boehringer Ingelheim, JB therapeutics, Sanofi-Aventis, novartis, UCB, GSK, Array 
Biopharma, Active Biotech, Galapagos, Inventiva, Medac, pfizer, Anamar and ruiYi, 
and is stock owner of 4d Science. od has received consultancy fees from 4d Science, 
Actelion, Active Biotech, Bayer, Biogenidec, BMS, Boehringer Ingelheim, Epipharm, 
Ergonex, esperare Foundation, Genentech/roche, GSK, Inventiva, Lilly, Medac, 
Medimmune, pharmacyclics, pfizer, Serodapharm, Sinoxa and UCB, and received 
research grants from Actelion, Bayer, Boehringer Ingelheim, Ergonex, pfizer and 
Sanofi, and has a patent mir-29 for the treatment of systemic sclerosis licensed. WJG 
has received teaching fees from pfizer. CA has served as a consultant for AbbVie, 
pfizer, roche, UCB, MSd, BMS and novartis, and has received research funding and 
speaker fees from AbbVie, pfizer, roche, UCB, MSd, BMS and novartis. FCH has 
received research funding from Actelion. MEA has undertaken advisory board work 
and received honoraria from Actelion, and received speaker’s fees from Bristol-Myers 
Squibb. nSd has done consultancy for AbbVie, pfizer, roche and MSd, and received 
speaker’s fees from AbbVie, Boehringer-Ingelheim, pfizer, richter Gedeon, roche and 
MSd. HG has done consultancy work and received honoraria from Actelion. UM-L 
is funded in part by EUStAr, EULAr and the European Community (desscipher 
programme). JMvL has received honoraria from Eli Lilly, pfizer, roche, MSd and BMS. 
Sp has received research grants from Actelion pharmaceuticals Australia, Bayer, 
GlaxoSmithKline Australia and pfizer, and speaker fees from Actelion. Ar receives 
funding from AstraZeneca. Cpd has done consultancy for GSK, Actelion, Bayer, 
Inventiva and Merck-Serono, received research grant funding from GSK, Actelion, 
CSL Behring and Inventiva, received speaker’s fees from Bayer and given trial advice 
to Merck-Serono.
ethics approval the ethics committee of each participating centre approved the 
study.
Provenance and peer review not commissioned; externally peer reviewed.
Open Access this is an open Access article distributed in accordance with the 
Creative Commons Attribution non Commercial (CC BY-nC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. no commercial use is permitted unless otherwise 
expressly granted.
RefeRences
 1 Clements p, Lachenbruch p, Siebold J, et al. Inter and intraobserver variability of 
total skin thickness score (modified rodnan tSS) in systemic sclerosis. J Rheumatol 
1995;22:1281–5.
570 Herrick AL, et al. Ann Rheum Dis 2018;77:563–570. doi:10.1136/annrheumdis-2017-211912
Clinical and epidemiological research
 2 Clements pJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and 
correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine 
trial. Arthritis Rheum 2000;43:2445–54.
 3 Amjadi S, Maranian p, Furst dE, et al. Course of modified rodnan skin score in 
systemic sclerosis clinical trials: analysis of 3 large multicenter, randomized clinical 
trials. Arthritis Rheum 2009;60:2490–8.
 4 Steen Vd, Medsger tA, rodnan Gp. d-penicillamine therapy in progressive systemic 
sclerosis (scleroderma): a retrospective analysis. Ann Intern Med 1982;97:652–9.
 5 Clements pJ, Furst dE, Wong WK, et al. High-dose versus low-dose d-penicillamine 
in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, 
controlled clinical trial. Arthritis Rheum 1999;42:1194–203.
 6 Stevens W, Vancheeswaran r, Black CM, et al. Alpha interferon-2a (roferon-A) in the 
treatment of diffuse cutaneous systemic sclerosis: a pilot study. UK Systemic Sclerosis 
Study Group. Br J Rheumatol 1992;31:683–9.
 7 Black CM, Silman AJ, Herrick AI, et al. Interferon-alpha does not improve outcome 
at one year in patients with diffuse cutaneous scleroderma: results of a randomized, 
double-blind, placebo-controlled trial. Arthritis Rheum 1999;42:299–305.
 8 denton Cp, Merkel pA, Furst dE, et al. recombinant human anti-transforming 
growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, 
randomized, placebo-controlled phase I/II trial of CAt-192. Arthritis Rheum 
2007;56:323–33.
 9 pope JE, Bellamy n, Seibold Jr, et al. A randomized, controlled trial of methotrexate 
versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351–8.
 10 Khanna d, Clements pJ, Furst dE, et al. recombinant human relaxin in the treatment 
of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, 
placebo-controlled trial. Arthritis Rheum 2009;60:1102–11.
 11 van Laar JM, Farge d, Sont JK, et al. Autologous hematopoietic stem cell 
transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic 
sclerosis: a randomized clinical trial. JAMA 2014;311:2490–8.
 12 Khanna d, denton Cp, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab 
in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. 
Lancet 2016;387:2630–40.
 13 Maurer B, Graf n, Michel BA, et al. prediction of worsening of skin fibrosis in patients 
with diffuse cutaneous systemic sclerosis using the EUStAr database. Ann Rheum Dis 
2015;74:1124–31.
 14 dobrota r, Maurer B, Graf n, et al. prediction of improvement in skin fibrosis 
in diffuse cutaneous systemic sclerosis: a EUStAr analysis. Ann Rheum Dis 
2016;75:1743–8.
 15 Herrick AL, pan x, peytrignet S, et al. treatment outcome in early diffuse cutaneous 
systemic sclerosis: the European Scleroderma observational Study (ESoS). Ann Rheum 
Dis 2017;76:1207–18.
 16 Leroy EC, Black C, Fleischmajer r, et al. Scleroderma (systemic sclerosis): 
classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
 17 Khanna d, Furst dE, Hays rd, et al. Minimally important difference in diffuse systemic 
sclerosis: results from the d-penicillamine study. Ann Rheum Dis 2006;65:1325–9.
 18 domsic rt, Lucas M, Steen Vd, et al. A clinical risk prediction model for skin thickness 
progression in early diffuse scleroderma. Arthritis Rheum 2016;68.
 19 Wiese AB, Berrocal VJ, Furst dE, et al. Correlates and responsiveness to change of 
measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. 
Arthritis Care Res 2014;66:1731–9.
 20 Smith GC, Seaman Sr, Wood AM, et al. Correcting for optimistic prediction in small 
data sets. Am J Epidemiol 2014;180:318–24.
 21 Steyerberg EW, Vickers AJ, Cook nr, et al. Assessing the performance of 
prediction models: a framework for traditional and novel measures. Epidemiology 
2010;21:128–38.
 22 Khanna d, denton Cp, Jagerschmidt A, et al. SAr100842, an antagonist of 
lysophosphatidic acid receptor 1, as a potential treatment for patients with systemic 
sclerosis: results from a phase 2a study. Arthritis Rheumatol 2014;66:S387.
